Evaluating the Effect of Rimegepant Versus Oral Triptans Use on Patient-Reported Outcomes Among Adults with Migraine in the United States (P10-12.002)
This study sought to compare patient-reported outcomes and healthcare resource use (HCRU) for individuals using rimegepant or triptans for acute treatment of migraine.
Authors
- Jessica Cirillo
- Simon Dagenais (ORCID: https://orcid.org/0000-0003-3062-9312)
- Karin Hygge Blakeman (ORCID: https://orcid.org/0000-0001-6925-7099)
- Nemin Chen
- Jessica Ailani (ORCID: https://orcid.org/0000-0001-8106-4927)
- Feng Dai (ORCID: https://orcid.org/0000-0002-9963-6863)
- Alexis Turko
Institutions
- Oracle (United States) (US)
- Pfizer (United States) (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211301
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00